Department of Medicine, MetroWest Medical Center, Framingham, MA, U.S.A.
Division of Medical Oncology, Department of Medicine, Kansas University Medical Center, Kansas City, KS, U.S.A.
Anticancer Res. 2020 Mar;40(3):1495-1502. doi: 10.21873/anticanres.14094.
BACKGROUND/AIM: Previous association studies have linked the functional miR-146a SNP rs2910164 with risk of digestive system cancer; however, the results of these studies are inconclusive and inconsistent. The objective of the following study is to provide an up-to-date and comprehensive meta-analysis of the association of miR-146a rs2910164 and digestive system cancer risk.
We searched the PUBMED/MEDLINE and Cochrane/EBM databases. The following inclusion criteria were used for the study selection: i) Case-control studies; ii) studies with reported allelic frequency/genotype data; and iii) studies with reported association with risk of a digestive system cancer. The following exclusion criteria were used: Review article, meta-analysis, case report and case series; studies evaluating relationships of miR-146a rs2910164 with outcomes other than cancer incidence, such as cancer morbidity or mortality. Study quality was assessed using the Newcastle-Ottawa Scale and publication bias assessed graphically and numerically using Begg's funnel plot and Egger's regression test and rank test. Outcome measure was the pooled odds ratios under the allelic frequency, dominant, recessive, and over-dominant models. Subgroup analysis was conducted for country of study origin.
No association of miR-146a rs2910164 with overall risk of digestive system cancer was identified. However, subgroup analysis showed an association with overall risk in the European population in the over-dominant model. Furthermore, miR-146a rs2910164 was associated with reduced risk of gastric cancer in the dominant model (pooled odds ratio=0.91, 95% confidence intervaI=0.83-0.99), increased risk of colorectal cancer under the recessive model and reduced risk of colorectal cancer under the over-dominant model in the European population. No significant within-study or publication biases were detected.
miR-146a rs2910164 was not associated with overall risk of digestive system neoplasms. However, the GG genotype and the CC genotype may be linked to higher risk of gastric cancer and colorectal cancer, respectively; and the CG genotype may be protective against digestive system neoplasms overall in the European population, especially for colorectal cancer.
背景/目的：先前的关联研究表明，miR-146a 功能 SNP rs2910164 与消化系统癌症的风险相关；然而，这些研究的结果并不一致。本研究旨在提供 miR-146a rs2910164 与消化系统癌症风险关联的最新和全面的荟萃分析。
我们搜索了 PUBMED/MEDLINE 和 Cochrane/EBM 数据库。本研究纳入标准为：i）病例对照研究；ii）报告等位基因频率/基因型数据的研究；iii）报告与消化系统癌症风险相关的研究。排除标准为：综述文章、荟萃分析、病例报告和病例系列；评估 miR-146a rs2910164 与癌症发病率以外的结果，如癌症发病率或死亡率关系的研究。使用纽卡斯尔-渥太华量表评估研究质量，并使用贝叶斯漏斗图和 Egger 回归检验和秩检验图形和数值评估发表偏倚。结局指标为等位基因频率、显性、隐性和超显性模型下的合并优势比。按研究来源国进行亚组分析。
miR-146a rs2910164 与消化系统癌症的总体风险无显著关联。然而，亚组分析显示，在欧洲人群中，超显性模型与总体风险相关。此外，miR-146a rs2910164 与胃癌的显性模型下的风险降低相关（合并优势比=0.91，95%置信区间=0.83-0.99），在欧洲人群中，结直肠癌的隐性模型下风险增加，超显性模型下风险降低。未发现研究内或发表偏倚。
miR-146a rs2910164 与消化系统肿瘤的总体风险无关。然而，GG 基因型和 CC 基因型可能与胃癌和结直肠癌的风险增加有关；CG 基因型可能对欧洲人群的消化系统肿瘤有保护作用，尤其是对结直肠癌。
